Influenza presentations and use of neuraminidase inhibitors by Australian general practice registrars : a cross-sectional analysis from the ReCEnT study
© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ..
OBJECTIVE: This study aims to establish prevalence and associations of (1) influenza and influenza-like illness (IILI) presentations to Australian general practice (GP) registrars (trainees) and (2) the use of neuraminidase inhibitors (NAIs) by GP registrars for new presentations of IILI, for the 10 years leading up to the COVID-19 pandemic in Australia (2010-2019).
DESIGN: This was a cross-sectional analysis of the Registrar Clinical Encounters in Training ongoing inception cohort study of the in-consultation experience and clinical behaviours of GP registrars. Data are collected by individual registrars three times (from 60 consecutive consultations each time) at 6 monthly intervals. Data include diagnoses/problems managed and medicines prescribed, along with multiple other variables. Univariate and multivariable logistic regression was used to establish associations of registrars seeing patients with IILI and of prescribing NAIs for IILI.
SETTING: Teaching practices within the Australian general practitioner specialist vocational training programme. Practices were located in five of the six Australian states (plus one territory).
PARTICIPANTS: GP registrars in each of their three compulsory 6-month GP training terms.
RESULTS: From 2010 to 2019, 0.2% of diagnoses/problems seen by registrars were IILI. 15.4% of new IILI presentations were prescribed an NAI. IILI diagnoses were less likely in younger (0-14) and older (65+) age groups, and more likely in an area of higher socioeconomic advantage. There was considerable variation in NAI prescribing between regions. There was no significant association of prescribing NAIs with age or Aboriginal and/or Torres Strait Islander patients.
CONCLUSIONS: IILI presentations were more likely among working-age adults and not among those groups at higher risk. Similarly, high-risk patient groups who would benefit most were not more likely to receive NAIs. The epidemiology and management of IILI has been distorted by the COVID-19 pandemic, but the burden of influenza in vulnerable populations must not be overlooked. Appropriately targeted antiviral therapy with NAIs influences outcomes for vulnerable patients. General practitioners manage the majority of IILI in Australia, and understanding GP IILI presentation and NAI prescribing patterns is a key first step to enabling sound and rational prescribing decisions for better patient outcomes.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Family medicine and community health - 11(2023), 2 vom: 01. Juni |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Moller, Chris [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 20.06.2023 Date Revised 30.01.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1136/fmch-2022-002107 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM358298458 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM358298458 | ||
| 003 | DE-627 | ||
| 005 | 20240131231849.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1136/fmch-2022-002107 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1276.xml |
| 035 | |a (DE-627)NLM358298458 | ||
| 035 | |a (NLM)37328280 | ||
| 035 | |a (PII)e002107 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Moller, Chris |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Influenza presentations and use of neuraminidase inhibitors by Australian general practice registrars |b a cross-sectional analysis from the ReCEnT study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.06.2023 | ||
| 500 | |a Date Revised 30.01.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. | ||
| 520 | |a OBJECTIVE: This study aims to establish prevalence and associations of (1) influenza and influenza-like illness (IILI) presentations to Australian general practice (GP) registrars (trainees) and (2) the use of neuraminidase inhibitors (NAIs) by GP registrars for new presentations of IILI, for the 10 years leading up to the COVID-19 pandemic in Australia (2010-2019) | ||
| 520 | |a DESIGN: This was a cross-sectional analysis of the Registrar Clinical Encounters in Training ongoing inception cohort study of the in-consultation experience and clinical behaviours of GP registrars. Data are collected by individual registrars three times (from 60 consecutive consultations each time) at 6 monthly intervals. Data include diagnoses/problems managed and medicines prescribed, along with multiple other variables. Univariate and multivariable logistic regression was used to establish associations of registrars seeing patients with IILI and of prescribing NAIs for IILI | ||
| 520 | |a SETTING: Teaching practices within the Australian general practitioner specialist vocational training programme. Practices were located in five of the six Australian states (plus one territory) | ||
| 520 | |a PARTICIPANTS: GP registrars in each of their three compulsory 6-month GP training terms | ||
| 520 | |a RESULTS: From 2010 to 2019, 0.2% of diagnoses/problems seen by registrars were IILI. 15.4% of new IILI presentations were prescribed an NAI. IILI diagnoses were less likely in younger (0-14) and older (65+) age groups, and more likely in an area of higher socioeconomic advantage. There was considerable variation in NAI prescribing between regions. There was no significant association of prescribing NAIs with age or Aboriginal and/or Torres Strait Islander patients | ||
| 520 | |a CONCLUSIONS: IILI presentations were more likely among working-age adults and not among those groups at higher risk. Similarly, high-risk patient groups who would benefit most were not more likely to receive NAIs. The epidemiology and management of IILI has been distorted by the COVID-19 pandemic, but the burden of influenza in vulnerable populations must not be overlooked. Appropriately targeted antiviral therapy with NAIs influences outcomes for vulnerable patients. General practitioners manage the majority of IILI in Australia, and understanding GP IILI presentation and NAI prescribing patterns is a key first step to enabling sound and rational prescribing decisions for better patient outcomes | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Education | |
| 650 | 4 | |a Family Practice | |
| 650 | 4 | |a General Practice | |
| 650 | 4 | |a Infectious Disease Medicine | |
| 650 | 4 | |a Physicians, Family | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a Central Nervous System Depressants |2 NLM | |
| 650 | 7 | |a Neuraminidase |2 NLM | |
| 650 | 7 | |a EC 3.2.1.18 |2 NLM | |
| 700 | 1 | |a van Driel, Mieke |e verfasserin |4 aut | |
| 700 | 1 | |a Davey, Andrew |e verfasserin |4 aut | |
| 700 | 1 | |a Tapley, Amanda |e verfasserin |4 aut | |
| 700 | 1 | |a Holliday, Elizabeth G |e verfasserin |4 aut | |
| 700 | 1 | |a Fielding, Alison |e verfasserin |4 aut | |
| 700 | 1 | |a Davis, Joshua |e verfasserin |4 aut | |
| 700 | 1 | |a Ball, Jean |e verfasserin |4 aut | |
| 700 | 1 | |a Ralston, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Turner, Alexandria |e verfasserin |4 aut | |
| 700 | 1 | |a Mulquiney, Katie |e verfasserin |4 aut | |
| 700 | 1 | |a Spike, Neil |e verfasserin |4 aut | |
| 700 | 1 | |a Fitzgerald, Kristen |e verfasserin |4 aut | |
| 700 | 1 | |a Magin, Parker |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Family medicine and community health |d 2016 |g 11(2023), 2 vom: 01. Juni |w (DE-627)NLM276367251 |x 2009-8774 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2023 |g number:2 |g day:01 |g month:06 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1136/fmch-2022-002107 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2023 |e 2 |b 01 |c 06 | ||